Annual report pursuant to Section 13 and 15(d)

Earnings (Loss) Per Common Share (Tables)

v3.20.2
Earnings (Loss) Per Common Share (Tables)
12 Months Ended
Jun. 30, 2020
Earnings (Loss) Per Common Share  
Schedule of Earnings (loss) Per Share, Basic and Diluted

The following table summarizes the components of the earnings (loss) per common share calculation (in thousands, except per share amounts):

 

 

 

 

 

 

 

 

 

 

Years ended

 

 

June 30, 

 

    

2020

    

2019

Basic and diluted numerator:

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss attributable to iBio, Inc. stockholders

    

$

(16,439)

    

$

(17,593)

Deemed dividends – down round of Series A Preferred and Series B Preferred

 

 

(21,560)

 

 

 —

Preferred stock dividends – iBio CMO Preferred Tracking Stock

 

 

(261)

 

 

(260)

Net loss available to iBio, Inc. stockholders

 

$

(38,260)

 

$

(17,853)

 

 

 

 

 

 

 

Basic and diluted denominator:

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted-average common shares outstanding

 

 

62,795

 

 

18,926

 

 

 

 

 

 

 

Per share amount

 

$

(0.61)

 

$

(0.94)

 

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share

As of June 30, 2020, and 2019, shares issuable which could potentially dilute future earnings included were as follows.

 

 

 

 

 

 

 

 

Year Ended

 

 

June 30,

 

    

2020

    

2019

 

 

(in thousands)

Stock options

 

3,476

 

1,347

Series A Preferred

 

 —

 

4,430

Series B Preferred

    

28,925

    

6,428

Restricted stock units

 

41

 

 —

Shares excluded from the calculation of diluted loss per share

 

32,442

 

12,205